Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultra-concentrated rapid acting insulin aspart - Arecor

Next Previous
Drug Profile

Ultra-concentrated rapid acting insulin aspart - Arecor

Alternative Names: AT-278; Ultra-concentrated rapid acting insulin - Arecor

Latest Information Update: 28 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arecor
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetes mellitus
  • No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 28 Mar 2026 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In the elderly, In adults) in Austria (SC, Injection)
  • 15 Sep 2025 Updated pharmacodynamics and pharmacokinetics data from a phase I trial in Type 2 diabetes mellitus presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD-2025)
  • 27 Jun 2025 Phase-II clinical trials in Diabetes mellitus (SC), prior to June 2025 (Arecor pipeline, June 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top